Thromb Haemost 2009; 101(04): 682-686
DOI: 10.1160/TH08-06-0368
Rapid and Short Communication
Schattauer GmbH

EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction

Authors

  • Peter Seizer

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Oliver Borst

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Harald F. Langer

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Andreas Bültmann

    2   Corimmun GmbH, Martinsried, Germany
  • Götz Münch

    2   Corimmun GmbH, Martinsried, Germany
  • Yared Herouy

    3   Dermatologische Universitätsklinik Freiburg, Freiburg, Germany
  • Konstantinos Stellos

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Björn Krämer

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Boris Bigalke

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Berthold Büchele

    4   Institute of Pharmacololgy of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany
  • Max G. Bachem

    5   Department of Clinical Chemistry and Pathobiochemistry, University of Ulm, Ulm, Germany
  • Dietmar Vestweber

    6   Department of Vascular Cell Biology, Max-Planck Institute for Molecular Biomedicine, Münster, Germany
  • Thomas Simmet

    4   Institute of Pharmacololgy of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany
  • Meinrad Gawaz

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany
  • Andreas E. May

    1   Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany

Financial support: Financial support: This study was supported by the Wilhelm-Sander-Stiftung Nr. 2006.059.1 (to PS, AEM), the Novartis-Stiftung (to HL, AEM and MG), the Deutsche Forschungsgemeinschaft SFB-TR19 (to AEM and MG) and by a research grant from the German Cardiac Society (Pfizer Stipendium) to HL.
Further Information

Publication History

Received: 11 June 2008

Accepted after major revision: 06 January 2009

Publication Date:
23 November 2017 (online)

Preview

Summary

The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147, basigin) is an immunoglobulin-like receptor expressed in various cell types. During cellular interactions homotypic EMMPRIN-EMMPRIN interactions are known to induce the synthesis of matrix metalloproteinases. Recently, we have identified EMMPRIN as a novel receptor on platelets. To our knowledge EMMPRIN has not been shown to serve as adhesion receptor, yet. Here we characterise platelet glycoprotein VI (GPVI) as a novel adhesion receptor for EMMPRIN. Human platelets were prestimulated with ADP and perfused over immobilised recombinant EMMPRIN-Fc or Fc-fragments under arterial shear conditions. ADP-stimulated platelets showed significantly enhanced rolling (but not enhanced firm adhesion) on immobilised EMMPRIN-Fc compared to Fc. Pretreatment of platelets with blocking mAbs anti-EMMPRIN or anti-GPVI leads to a significant reduction of rolling platelets on immobilised EMMPRIN-Fc, whereas pretreatment with blocking mAbs anti-p-selectin, anti-α4-integrin or anti-GPIIb/IIIa complex (20 μg/ml each) had no effect. Consistently, chinese hamster ovary (CHO) cells stably transfected with GPVI showed enhanced rolling (but not adhesion) on immobilised EMMPRIN-Fc in comparison to nontransfected CHO cells. Similarly, CHO cells stably transfected with EMMPRIN showed enhanced rolling on immobilised GPVIFc (or EMMPRIN-Fc) compared to non transfected CHO-cells. Finally, specific binding of EMMPRIN to GPVI was demonstrated by a modified ELISA and surface plasmon resonance technology with a dissociation constant of 88 nM. Platelet GPVI is a novel receptor for EMMPRIN and can mediate platelet rolling via GPVIEMMPRIN interaction.